Bis-chloroethylnitrosourea (BCNU) is currently used as an anti-cancer drug for glioblastoma therapy. In this study, BCNU was loaded into the hydrophobic cores of R3V6 amphiphilic peptide micelles for efficient delivery into brain tumors. The scanning electron microscope (SEM) study showed that the BCNU-loaded R3V6 peptide micelles (R3V6-BCNU) formed spherical micelles. MTT assay showed that R3V6-BCNU more efficiently induced cell death in C6 glioblastoma cells than did BCNU. In the Annexin V assay, R3V6-BCNU more efficiently induced apoptosis than did BCNU alone. Furthermore, the results showed that R3V6 was not toxic to cells. The positive charges of the R3V6 peptide micelles may facilitate the interaction between R3V6-BCNU and the cellula...
Background: Glioblastoma (GBM) is the most common and deadliest malignant primary brain tumor, contr...
Effective treatment of glioma and other central nervous system (CNS) diseases is hindered by the pre...
Glioma brain tumors account for 49% of all primary brain tumors in the US every year and greater tha...
An amphiphilic peptide with a 3-arginine stretch and a 6-valine stretch was evaluated as a gene carr...
AbstractGlioblastoma-targeted drug delivery systems facilitate efficient delivery of chemotherapeuti...
Glioblastoma multiforme is the most aggressive form of malignant brain tumor with poor prognosis. Th...
Dbait is a small double-stranded DNA molecule that has been utilized as a radiosensitizer to enhance...
YuKun Huang,1 Wenchao Liu,1 Feng Gao,1 Xiaoling Fang,2 Yanzuo Chen1 1Department of Pharmaceutics, S...
Compared to that of other tumors, various barriers, such as the blood brain barrier (BBB), enzymatic...
Malignant glioma, the most frequent and aggressive central nervous system (CNS) tumor, severely thre...
The treatment of glioma is a great challenge because of the existence of the blood-brain barrier (BB...
Aminopeptidase N (APN), recognized by Asn-Gly-Arg (NGR) peptides, is expressed in the pericytes asso...
International audienceGlioblastoma stem cells correspond to brain tumor-initiating cells (BTICs) tha...
Dan Zou,1 Wei Wang,1 Daoxi Lei,1 Ying Yin,1 Peng Ren,1 Jinju Chen,2 Tieying Yin,1 Bochu Wang,1 Guixu...
Treatment of glioma remains a critical challenge worldwide, since the therapeutic effect is greatly ...
Background: Glioblastoma (GBM) is the most common and deadliest malignant primary brain tumor, contr...
Effective treatment of glioma and other central nervous system (CNS) diseases is hindered by the pre...
Glioma brain tumors account for 49% of all primary brain tumors in the US every year and greater tha...
An amphiphilic peptide with a 3-arginine stretch and a 6-valine stretch was evaluated as a gene carr...
AbstractGlioblastoma-targeted drug delivery systems facilitate efficient delivery of chemotherapeuti...
Glioblastoma multiforme is the most aggressive form of malignant brain tumor with poor prognosis. Th...
Dbait is a small double-stranded DNA molecule that has been utilized as a radiosensitizer to enhance...
YuKun Huang,1 Wenchao Liu,1 Feng Gao,1 Xiaoling Fang,2 Yanzuo Chen1 1Department of Pharmaceutics, S...
Compared to that of other tumors, various barriers, such as the blood brain barrier (BBB), enzymatic...
Malignant glioma, the most frequent and aggressive central nervous system (CNS) tumor, severely thre...
The treatment of glioma is a great challenge because of the existence of the blood-brain barrier (BB...
Aminopeptidase N (APN), recognized by Asn-Gly-Arg (NGR) peptides, is expressed in the pericytes asso...
International audienceGlioblastoma stem cells correspond to brain tumor-initiating cells (BTICs) tha...
Dan Zou,1 Wei Wang,1 Daoxi Lei,1 Ying Yin,1 Peng Ren,1 Jinju Chen,2 Tieying Yin,1 Bochu Wang,1 Guixu...
Treatment of glioma remains a critical challenge worldwide, since the therapeutic effect is greatly ...
Background: Glioblastoma (GBM) is the most common and deadliest malignant primary brain tumor, contr...
Effective treatment of glioma and other central nervous system (CNS) diseases is hindered by the pre...
Glioma brain tumors account for 49% of all primary brain tumors in the US every year and greater tha...